Innocan Pharma Corp. Stock
€0.11
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Innocan Pharma Corp.
sharewise wants to provide you with the best news and tools for Innocan Pharma Corp., so we directly link to the best financial data sources.
Financials
News
InnoCan Pharma Stock: Nasdaq Listing Filing Signals Major Leap
InnoCan Pharma has officially filed registration documents with the SEC for a Nasdaq listing on July 23, 2025, marking a transformative moment for the Israeli-Canadian biotech company. The
Innocan’s Findings to be Showcased in Scientific Poster Reception at PAINWeek 2025 Conference in Las Vegas, Nevada
- PAINWeek is the premier US conference in pain management
- Innocan’s Poster “Is Long-Acting Synthetic Cannabidiol a Solution to Chronic Pain?” to be highlighted
Innocan Pharma Announces Details of Proposed Share Consolidation
HERZLIYA, Israel and CALGARY, Alberta – August 29, 2025 – Innocan Pharma Corporation (“Innocan” or the “Company”) (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that further to
Innocan Pharma Announces First Half Of 2025 Financial Results
Herzliya, Israel and Calgary, Alberta – August 27, 2025 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company
Innocan Pharma Announces Public Filing of Registration Statement for Proposed U.S. Public Offering
HERZLIYA, Israel and CALGARY, Alberta – July 23, 2025 – Innocan Pharma Corporation (“Innocan” or the “Company”) (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has
Innocan Pharma Announces Promising Results of LPT-CBD Administered to Gottingen Minipigs, providing a good translational model and Provides Corporate Update
Herzliya, Israel and Calgary, Alberta –July 3, 2025 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
Herzliya, Israel and Calgary, Alberta – June 20, 2025 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and